Abbott Laboratories has issued an alert for its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitors, which have been linked to 7 deaths and over 700 injuries worldwide due to faulty readings ...

A newly issued alert links certain FreeStyle Libre 3 and 3 Plus glucose-monitoring sensors to at least seven deaths and ...

The Food and Drug Administration has issued an alert concerning two glucose monitors with a “high-risk” sensor issue. Abbott Diabetes Care initiated a “medical device correction” on Nov. 24, for ...

The decision to recall approximately three million sensors follows reports of potentially life-threatening errors in the ...

About 3 million glucose monitoring sensors were potentially affected by a production error that caused incorrect low glucose readings.

Some FreeStyle Libre 3 glucose sensors made by Abbott Diabetes Care may give incorrect low readings. The devices have been ...

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

A literature search was carried out for this briefing in accordance with the interim process and methods statement. This briefing includes the most relevant or best available published evidence ...

They say a rising tide lifts all boats, and that certainly seems to be the case with the new wave of drugs and devices for diabetes management. In a recent analysis (PDF), Abbott examined trends in ...

Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin.

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...